Clinical trials: Intravenous Infusions
Solid Tumours
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
- Trial name
- NCT00497679
- Testing
- AZD1152
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Healthy Elderly Subjects
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects
It is a single-center, open-label, dose-finding, Phase I clinical study evaluating the pharmacokinetics, pharmacodynamics, and safety characteristics of HSK3486 in healthy elderly subjects.
- Trial name
- NCT04197661
- Testing
- HSK3486
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Carcinoma, Small Cell, Small Cell Lung Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
- Trial name
- NCT00298896
- Testing
- SNS-595
- Where
- 17 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Sunesis Pharmaceuticals
Heart Decompensation, Acute
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.
- Trial name
- NCT02932969
- Testing
- BMS-986231
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg) BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood coagulation parameters
- Trial name
- NCT02254083
- Testing
- BIBT 986 BS - low, BIBT 986 BS - high
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cardiac Diseases
A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography
This is a phase III, prospective, multicenter, open-label, crossover study of the safety and efficacy of NH002-enhanced echocardiography in adult subjects with suboptimal images on non-contrast 2D transthoracic echocardiography…
- Trial name
- NCT07740421
- Testing
- NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- Volunteers
- 150 people
- Sponsor
- Trust Bio-sonics, Inc.
Safety and Tolerability in Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects
To evaluate the safety, tolerability, and pharmacokinetics of SSS39 injection in healthy Chinese subjects
- Trial name
- NCT07057726
- Testing
- SSS39
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gastric Cancer
Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
- Trial name
- NCT04181333
- Testing
- TRASTUZUMAB BS
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Healthy
A Study To Understand How The Body Reacts To A Low Dose Of PF-06427878 When Given In A Vein To Healthy, Adult, Males
To determine how the body reacts to a low dose of PF-06427878 when given in a vein over 30 minutes to healthy, adult, males.
- Trial name
- NCT02237742
- Testing
- PF-06427878
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic…
- Trial name
- NCT01851070
- Testing
- Allogeneic Mesenchymal Precursor Cells, Normal Saline
- Where
- 23 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Mesoblast, Ltd.
Tuberculosis, Pulmonary
Efficacy and Safety of Intravenous Treatment of Tuberculosis
This Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study will compare the efficacy and safety of intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of…
- Trial name
- NCT04150367
- Testing
- Isoniazid, Rifampicin, Ethambutol
- Where
- 9 sites in Ukraine
- Volunteers
- 166 people
- Sponsor
- Yuria-Pharm
Healthy Volunteers, Heart Failure
A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants
This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people.
- Trial name
- NCT07656454
- Testing
- CDR132L (i.v.), CDR132L (s.c.)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males
To compare the pharmacokinetics of levetiracetam following single and multiple 15-minute intravenous infusions of 1500 mg levetiracetam between Japanese and Caucasian healthy male subjects
- Trial name
- NCT01725009
- Testing
- Multiple 15-minute intravenous infusions of 1500 mg levetiracetam
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- UCB Japan Co. Ltd.
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
- Trial name
- STRIVE-ON (NCT05995405)
- Testing
- GTX-104, Nimotop 30 MG Oral Capsule
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grace Therapeutics Inc.
Neoplasm Malignant
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR566658 Secondary Objectives: To characterize the safety profile of SAR566658 To evaluate the pharmacokinetic profile of SAR566658 To assess the potential…
- Trial name
- NCT01156870
- Testing
- SAR566658
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT07355868
- Testing
- REGEND007
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Healthy Volunteers
A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Single center, randomized, double-blind, placebo-controlled, adaptive sequential ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of single doses of deferiprone administered by intravenous…
- Trial name
- NCT01989455
- Testing
- Deferiprone
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Biliary Tract Cancer
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing…
- Trial name
- NCT05835778
- Where
- 24 sites in Japan
- Volunteers
- 236 people
- Sponsor
- AstraZeneca
Congenital Bleeding Disorder, Haemophilia A
Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of NNC 0128-0000-2011 compared to NNC 0128-0000-2021 when given for…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01272206
- Testing
- NNC 0128-0000-2011, NNC 0128-0000-2021
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Novo Nordisk A/S
Advanced or Metastatic Solid Tumors
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting…
- Trial name
- Ulysse (NCT03316638)
- Testing
- W0101 - Cohort A1, W0101 - Cohort A2, W0101 - Expansion Phase
- Where
- 3 sites in France, Spain
- Volunteers
- 316 people
- Sponsor
- Pierre Fabre Medicament